Cellectis S.A. (CLLS): Price and Financial Metrics


Cellectis S.A. (CLLS)

Today's Latest Price: $17.85 USD

0.50 (2.88%)

Updated Sep 25 4:00pm

Add CLLS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

CLLS Stock Summary

  • With a price/sales ratio of 8.7, Cellectis SA has a higher such ratio than 85.14% of stocks in our set.
  • With a year-over-year growth in debt of 69.94%, Cellectis SA's debt growth rate surpasses 84.24% of about US stocks.
  • Revenue growth over the past 12 months for Cellectis SA comes in at 299.44%, a number that bests 97.83% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Cellectis SA, a group of peers worth examining would be ZYME, BLUE, APTX, NKTR, and ARVN.
  • Visit CLLS's SEC page to see the company's official filings. To visit the company's web site, go to www.cellectis.com.
CLLS Daily Price Range
CLLS 52-Week Price Range

CLLS Stock Price Chart Technical Analysis Charts


CLLS Price/Volume Stats

Current price $17.85 52-week high $21.97
Prev. close $17.35 52-week low $7.32
Day low $17.26 Volume 94,184
Day high $17.86 Avg. volume 168,345
50-day MA $17.77 Dividend yield N/A
200-day MA $16.04 Market Cap 758.02M

Cellectis S.A. (CLLS) Company Bio


Cellectis SA is a preclinical stage biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. The company was founded in 1999 and is based in Paris, France.


CLLS Latest News Stream


Event/Time News Detail
Loading, please wait...

CLLS Latest Social Stream


Loading social stream, please wait...

View Full CLLS Social Stream

Latest CLLS News From Around the Web

Below are the latest news stories about Cellectis SA that investors may wish to consider to help them evaluate CLLS as an investment opportunity.

Cellectis (CLLS) Investor Presentation - Slideshow

The following slide deck was published by Cellectis S.A. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 11, 2020

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)NEW YORK, Sept. 07, 2020 (GLOBE NEWSWIRE) -- Listing market: Euronext GrowthISIN code: FR0010425595DateTotal number of shares in the capitalTotal number of voting  rights 08/31/202042,486,13347,940,778 About Cellectis Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of t...

Yahoo | September 7, 2020

Cellectis to Participate in Upcoming Investor Conferences

NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), will present at several upcoming investor conferences. Webcast information when available will be posted in the Investor Relations section of the Company’s website at https://www.cellectis.com/en/investors/events-and-webcasts/ Citi Annual BioPharma Conference September 9, 2020 from 3:20 PM to 4:05 PM EDT André Choulika, Chairman & CEO, to participate in a panel on Innovation in Cell Therapy.Wells Fargo Healthcare Conference Boston September 10, 2020 from 8:00 AM to 8:30 AM EDT André Choulika; Carrie Brownstein, CMO; Simon Harnest, VP, Corporate Strategy & Fi...

Yahoo | September 2, 2020

Cellectis S.A. (CLLS) CEO André Choulika on Q2 2020 Results - Earnings Call Transcript

Cellectis S.A. (CLLS) Q2 2020 Earnings Conference Call August 06, 2020 7:30 AM ET Company Participants Simon Harnest - Vice President-Corporate Strategy & Finance André Choulika - Chairman & Chief Executive Officer Carrie Brownstein - Chief Medical Officer Eric Dutang - Chief Financial Officer Conference Call Participants Jim Birchenough -...

SA Transcripts on Seeking Alpha | August 6, 2020

Cellectis to Hold Second Quarter 2020 Earnings Call on Thursday, August 6, 2020 at 7:30AM EDT

NEW YORK, July 29, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on…

GlobeNewswire | July 29, 2020

Read More 'CLLS' Stories Here

CLLS Price Returns

1-mo -1.71%
3-mo -0.50%
6-mo 94.02%
1-year 72.46%
3-year -35.02%
5-year -30.57%
YTD 4.26%
2019 2.82%
2018 -42.88%
2017 71.98%
2016 -45.38%
2015 N/A

Continue Researching CLLS

Want to see what other sources are saying about Cellectis SA's financials and stock price? Try the links below:

Cellectis SA (CLLS) Stock Price | Nasdaq
Cellectis SA (CLLS) Stock Quote, History and News - Yahoo Finance
Cellectis SA (CLLS) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7111 seconds.